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Abstract: Immunotherapy with Bacillus Calmette–Gue´rin (BCG) is
the most efficacious treatment for high-risk bladder cancer (BC) (Ta/T1
or carcinoma in situ) to reduce the risk of recurrence. Our aim was to
evaluate whether hypertension and diabetes influence the outcome of
patients with noninvasive BC treated with BCG instillations.
In order to collect homogeneous data, we considered as ‘‘hyperten-
sive’’ only those patients who had previous diagnosed hypertension and a
history of taking medical therapy with antihypertensive drugs (AHT), and
as ‘‘diabetic’’ only those prescribed oral antidiabetics or insulin (ADT).
We analyzed 343 high-risk BC patients undergoing BCG (1995–
2010) with a median follow-up of 116 months (range 48–238). The
distribution of various kinds of AHT and antidiabetic drugs was homo-
geneous, with no significant differences ( p> 0.05).
In both univariate and multivariate analyses, the only statistically
significant parameter prognostic for recurrence after BCG treatment was
AHT. Recurrence-free survival curves showed a significant correlation
with AHT ( p¼ 0.0168, hazards ratio [HR] 1.45, 95% confidence interval
[CI] 1.0692–1.9619); there was no correlation ( p¼ 0.9040) with ADT
(HR 0.9750, 95% CI 0.6457–1.4721). After stratification of AHT and
ADT according to drug(s) prescribed, there were no significant differ-
ences in the BC recurrence rate ( p> 0.05).
In this study with a very long-term follow-up, hypertension alone
(evaluated by AHT) revealed the increased risk of BC recurrence after
BCG treatment.
Several hypotheses have been formulated to support these findings,
but further prospective studies are needed to both evaluate the real
influence of hypertension and identify a possible prognostic factor to
be used in selecting poor-prognosis BC patients as early candidates for
surgical treatment.sandro Crestani, ettor, MD,
d Filiberto Zattoni, MDCalmette–Gue´rin, HDL = high-density lipoprotein, MetS =
metabolic syndrome.
INTRODUCTION
T he components of the metabolic syndrome (MetS) havebeen individually and/or cumulatively linked to the risk of
cancer.1 The mechanism underlying these associations is
unknown, although experimental and clinical studies indicate
the possible involvement of various biological processes.2
One problem in interpreting the results of published studies
on the correlation between MetS and cancer is often the
nonstandardized definition of MetS. The different weights
assigned to each MetS component may also generate different
hierarchical distributions, resulting in noncomparable data.
In 2003, the National Cholesterol Education Program-Adult
Treatment Panel III (NCEP-ATP III) developed a definition of
MetS, which required 3 or more of the following 5 factors to be
present: increased waist circumference (102/88 cm for men and
women, respectively), hypertriglyceridemia (8.33 mmol/L),
low high-density lipoprotein (HDL) cholesterol (<2.22 and
2.78 mmol/L for men and women), hypertension (130/85 mm
Hg), and elevated fasting glucose (5.5 mmol/L).3
Although the influence of MetS on the development of
several cancers (colorectal, pancreas, liver, and breast) has been
extensively reported, there are few data on the association
between MetS and the risk of bladder cancer (BC), for both
separate components and MetS factors combined.
Starting from the NCEP-ATP III definition, we first carried
out a retrospective cohort study (unpublished data) on the
influence of MetS on BC, demonstrating no significant corre-
lation between BC and body mass index (instead of waist
circumference), triglyceridemia, HDL-cholesterol, hyperten-
sion (p¼ 0.7866) or hyperglycemia (p¼ 0.6064).
We then focused on the group of patients with noninvasive
high-risk BC treated with instillations of Bacillus Calmette–
Gue´rin (BCG), examining several parameters, such as age, as
predictors of the response to immunotherapy.
According to European Association of Urology guidelines,
BCG is the most efficacious treatment for high-risk BC (Ta/T1 or
carcinoma in situ) to reduce the risk of recurrence.4 Its mechanism
of action continues to be poorly defined, but it has been shown to
involve a T-helper type 1 immunomodulatory response.
In order to collect homogeneous data, we did not directly
examine 2 of the components of MetS (hypertension and
diabetes) but antihypertensive (AHT) and antidiabetic (ADT)s to determine whether AHT and ADT,
n, could influence the response to BCG
h noninvasive BC.
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METHODS
From 1995 to 2010, we conducted a retrospective cohort
study on patients with diagnosed noninvasive high-risk BC,
treated with BCG instillations according to the standard scheme
of 6-weekly instillations (induction) and then 6-monthly ones
(maintenance cycle). We used a low BCG dose (27 mg), as
reported in our clinical study demonstrating the efficacy of this
low dosage, with significantly reduced side effects.5
Of the above components of MetS, we analyzed (alone or
in combination) only hypertension and diabetes but, for homo-
geneous data, we considered as ‘‘hypertensive’’ only those
patients who had previous diagnosed hypertension and a history
of taking medical therapy with AHT, and as ‘‘diabetic’’ only
those prescribed ADT.
We analyzed BC clinical stages (TNM classification) and
grading (G1, G2, G3; WHO, 1973) before BCG treatment,
recording data relating to BC follow-up, with cystoscopy and
urinary cytology, after the first 6-weekly instillation, after the 6-
monthly instillations, and during the further follow-up (until
March 2014). The finding of BC (any T, any G) during cysto-
scopy and/or positive urinary cytology was defined as ‘‘recur-
rent disease.’’
Ethical Approval
Ethical approval was not necessary in this retrospective
study.
Statistics
The McNemar test for univariate analysis was used to
compare categorical variables in the 2 groups. Cox multivariate
regression model was used to compare time-independent vari-
Dal Moro et alables. Recurrence-free data, considered as survival data, were
estimated with the Kaplan–Meier method and compared with
the log-rank test. Statistical significance was set at p< 0.05. All
TABLE 1. Patients’ Characteristics and Distribution of BC Gradin
Patients’ Characteristics
Gender Male %
293 85.4
Therapy AHT (%): 128 (37.3) No AHT (%): 215 (62
Grading G0–G2: 230 67
Distribution of BC Grading According to Therapy
Grading
G0–G2 % G3
Therapy
AHT 75 32.6 53 4
No AHT 155 67.4 60 5
ADT 22 9.6 24 2
No ADT 198 90.4 99 7
ADT¼ antidiabetic therapy, AHT¼ antihypertensive therapy, BC¼ blad
McNemar test.
2 | www.md-journal.comanalyses were performed with (MedCalc Software, Ostend,
Belgium) for Windows, version 13.1.
RESULTS
A total of 343 consecutive patients was analyzed, 293 men
and 50 women. The distribution of the various AHT and
antidiabetic drugs was homogeneous, without significant differ-
ences ( p> 0.05).
We found a significant correlation between AHT and ADT
and initial staging/grading of BC ( p¼ 0.0185 and P¼ 0.0147,
respectively), as shown in Table 1.
Median follow-up was 116 months (range 48–238), during
which recurrence of disease after BCG treatment was recorded
in 137 patients (39.9%). Patient characteristics and stratification
according to AHT and ADT relating to recurrence of disease
after BCG treatment are listed in Table 2.
Analysis of the risk of recurrence, according to both MetS
components evaluated, showed that ADT patients had a 43.5% of
risk of developing new BC after BCG treatment, whereas non-
ADT patients had a risk of 39.4% ( p¼ 0.5990, odds ratio
[OR]¼ 1.18, 95% confidence interval [CI] 0.6317–2.2169).
The risk of recurrence for AHT patients was 48.4% but only
34.9% in non-AHT patients ( p¼ 0.0136, OR¼ 1.75, 95% CI
1.1227–2.7388). When AHT and ADT patients were grouped
together, no significant differences were found ( p¼ 0.3904).
According to the AHT parameter, the recurrence-free survival
curves showed a significant correlation ( p¼ 0.0168, hazards
ratio [HR] 1.45, 95% CI 1.0692–1.9619) (Figure 1) but none
with the ADT parameter ( p¼ 0.9040, HR 0.9750, 95% CI
0.6457–1.4721). After stratification of AHT and ADT according
to drug, there were no significant differences in the BC recurrence
rate ( p> 0.05). Stratifying AHT, we found that in the group of
40 patients treated with angiotensin-converting enzyme inhibi-
Medicine  Volume 94, Number 9, March 2015tors, 21 (52.5%) had BC recurrence and 19 (47.5%) no recur-
rence; of the 27 cases taking diuretics, 12 (44.4%) had a
recurrence and 15 (55.4%) did not. In the group of 20 patients
g According to Therapy
Female %
50 14.6
.7) ADT (%): 46 (13.4) No ADT (%): 297 (86.6)
G3: 113 33
% p Value

OR 95% CI
6.9 0.0105 0.5478 0.3455–0.8686
3.1
1.2 0.0147 0.4583 0.2449–0.8578
8.8
der cancer, CI¼ confidence interval, OR¼ odds ratio.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Outcomes after BCG treatment
Recurrence % No Recurrence % p Value

OR 95% CI
AHT 62 48.4 66 51.6 0.0136 1.75 1.1227–2.7388
No AHT 75 34.9 140 65.1
ADT 20 43.5 26 56.5 0.5990 1.18 0.6317–2.2169
No ADT 117 39.4 180 60.6
AHTþADT 13 41.9 18 58.1 0.3904 1.402 0.6484–3.0311
No AHTþNo ADT 68 34 132 66
Ba
Medicine  Volume 94, Number 9, March 2015 Hypertension and Bladder Cancerwith hypertension treated with b-blockers, 9 (45%) had BC
recurrence and 55% (11) did not; of 14 patients using a calcium
channel blocker, 6 (42.9%) had a recurrence and 8 (57.1%) did
not; in the 27 patients taking a combination of drugs or other
medications, the distribution was 14 cases (51.8%) in the group
with BC recurrence and 13 (48.2%) in the other group ( p> 0.05).
In multivariate analysis (Table 3), the only statistically
significant parameter prognostic for recurrence after BCG
treatment was AHT ( p¼ 0.0185).
DISCUSSION
Despite the clear demonstration of a relation between MetS
and cancer, there are few data on the association between MetS
and the specific risk of BC. A recent large prospective study
showed that MetS is associated with a significant, albeit modest,
increase in BC risk in men, without evidence of synergy among
various MetS factors.6 The data showed that, among single
MetS components, only hypertension was significantly associ-
ated with risk in men; among women with high glucose, there
was a nonsignificant increase in risk. Other less extensive
studies have reported no associations.1
ADT¼ antidiabetic therapy, AHT¼ antihypertensive therapy, BCG¼
McNemar test.In our experience, we confirm (Dal Moro, 2012) that there
is no association among hypertension, diabetes and BMI,
and BC.
Time, mo
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No AHT
AHT
R
ec
ur
re
nc
e-
fre
e 
su
rv
iva
l p
ro
ba
bi
lity
,
 
%
20 40 60 80 10020
20
30
40
50
60
70
80
90
100
FIGURE 1. Kaplan–Meier recurrence-free survival among patients
with high-risk BC BCG-treated with AHT. AHT¼antihypertensive
therapy, BC¼bladder cancer.
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under controversial discussion, because several authors have
reported discordant results.7 In 1991, Grove et al8 analyzed a
large population in a 20-year prospective study and demonstrated
that there was no association between systolic and diastolic blood
pressure and total cancer incidence or death due to cancer.
However, another prospective study with a 14-year follow-up
found that both systolic and diastolic blood pressures were
significantly associated with subsequent mortality from cancer
(lung, colon, and all other sites combined).9
Several other prospective studies have provided evidence
indicating that hypertension in itself represents a significant risk
for malignancies, and the organ most frequently involved, even
in long-term prospective studies, is the kidney.10 However, little
is known about possible pathways between hypertension and
cancer.11
Some authors have suggested that AHT medications are
responsible for the excess mortality, although the effects of such
drugs on decreasing cardiovascular morbidity and mortality
have been extensively demonstrated.12 A review by Grossman
et al13 revealed that only diuretics seem to be carcinogenic for
renal cell carcinoma (risk ratio 1.55), whereas the association
between other AHT and malignancy was absent or even inverse
(the case of calcium antagonists).
In our series of hypertensive patients, there was a non-
significant correlation between BC and various kinds of AHT
and ADT, which meant that the variable ‘‘specific drug’’ could
not be evaluated.
The aim of our study was to analyze only a group of high-
risk BC patients treated with BCG, in order to evaluate the
influence of hypertension and diabetes on the response
to immunotherapy.
The mechanism of action of BCG therapy is not comple-
tely understood: the live attenuated strain of Mycobacterium
bovis instilled into the bladder induces the same type of
histologic and immunologic reaction as that found in patients
with tuberculosis. After being processed by macrophages, some
fragments combine with histocompatibility antigens and appear
on the cell surface, where they stimulate CD4þ T cells and
induce a primarily T-helper type 1 immune response, which
targets these cells for destruction. For BCG to be effective, the
host should be immunocompetent.
We demonstrate that patients with a history of taking drugs
to control hyperglycemia are not at risk of BC recurrence after
BCG treatment. Conversely, AHT seems to be related to a
cillus Calmette–Gue´rin, CI¼ confidence interval, OR¼ odds ratio.significantly higher risk of such recurrence than in patients with
no history of hypertension or use of AHT, with no differences
concerning sex, age or grading of cancer.14
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TABLE 3. Multivariate Analysis
Independent Variable Coefficient Standard Error t p Value

Age at onset 0.002567 0.002591 0.991 0.3225
ADT 0.01226 0.08007 0.153 0.8784
AHT 0.1482 0.05758 2.574 0.0185
Grading 0.01903 0.02284 0.833 0.4054
Dal Moro et al Medicine  Volume 94, Number 9, March 2015The relationship between blood pressure (and AHT) and
cancer may differ according to follow-up time: in our experi-
ence, considering the Kaplan–Meier curve related to AHT, the
gap between the 2 recurrence-free survival curves widens after
22 months. In the literature, 1 prospective study demonstrated
that only after 5 years of follow-up was there a positive
association between systolic (but not diastolic) blood pressure
and risk of cancer mortality.15
Our study has certain strengths. First, the number of cases
analyzed is high, considering patient characteristics (BCG-
treated BC). Second, the follow-up is impressive (from 4 to
19 years) and higher than other studies in the literature reporting
similar values. Third, as a single-center study, we excluded
possible bias in pathological analysis, because all histological
samples were analyzed by the same pathologist (M.P.G.).
This study also has some limitations. The first is its
retrospective characteristic, although all data were extracted
from our medical records; therefore, the possibility of selection
bias cannot be excluded. Second, we did not consider ‘‘hyper-
tension’’ but ‘‘antihypertensive therapy’’. The same applies to
‘‘diabetes’’ and ‘‘antidiabetic therapy’’, which are not properly
components of MetS. However, this choice did allow us to
standardize these parameters. In many published reports,
although the definition of ‘‘hypertension’’ is correct and stan-
dardized, it is possible that some false-positive patients were
included, in whom the recorded high blood pressure was only a
temporary alteration, perhaps due to the effect of hospitaliza-
tion.
Therefore, we cannot state definitely that the higher risk of
recurrence in hypertensive (treated) patients in comparison with
nonhypertensive ones is correlated primarily to hypertension or
AHT, although the distribution of the various kinds of drugs
makes this parameter nonsignificant.
Hypotheses
Considering the possible role of ‘‘hypertension’’ we can
propose some hypotheses.
We speculate that, when BCG treatment is ineffective, an
inadequate immunitary response is at work, perhaps caused by
several factors: first, blood pressure elevation has been demon-
strated to determine micro- (and macro-) vascular alterations
(such as atherosclerosis), giving rise to insufficient blood supply
and modifying the immunologic reaction to BCG. Second, the
proven relation between inflammation and hypertension,
through the activation of Th1 cells and the production of
neoantigens, may play a role in the altered immunitary response
ADT¼ antidiabetic therapy, AHT¼ antihypertensive therapy.
Cox multivariate regression model.to BCG.16 Innate and adaptive immune responses may contrib-
ute to this process, as alterations of the immune response have
been implicated in the genesis of hypertension, as demonstrated
4 | www.md-journal.comin several studies focusing on the possible role of immune
perturbations.17
CONCLUSIONS
The mechanisms involving the immune response to BCG
in hypertensive BC patients treated with BCG are still elusive,
and the findings of the present study may represent an inter-
esting starting point for further prospective studies, to evaluate
both the real influence of hypertension and to identify a possible
prognostic factor to be used in selecting poor-prognosis BC
patients as early candidates for surgical treatment.
To the best of our knowledge, no previous studies have
focused on the effects of single components of MetS and/or
specific therapies in relation to BC recurrence risk after
BCG therapy.
ACKNOWLEDGMENTS
None.
REFERENCES
1. Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk
of cancer: a systematic review and meta-analysis. Diabetes Care.
2012;35:2402–2411.
2. Hursting SD, Hursting MJ. Growth signals, inflammation, and
vascular perturbations: mechanistic links between obesity, metabolic
syndrome, and cancer. Arterioscler Thromb Vasc Biol.
2012;32:1766–1770.
3. Lipsy RJ. The National Cholesterol Education Program Adult
Treatment Panel III guidelines. J Manag Care Pharm. 2003;9:2–5.
4. Kawai K, Miyazaki J, Joraku A, et al. Bacillus Calmette–Gue´rin
(BCG) immunotherapy for bladder cancer: current understanding and
perspectives on engineered BCG vaccine. Cancer Sci. 2013;104:22–
27.
5. Pagano F, Bassi P, Milani C, et al. A low dose Bacillus Calmette–
Gue´rin regimen in superficial bladder cancer therapy: is it effective?
J Urol. 1991;146:32–34.
6. Ha¨ggstro¨m C, Stocks T, Rapp K, et al. Metabolic syndrome and risk
of bladder cancer: prospective cohort study in the metabolic
syndrome and cancer patients (Me-Can). Int J Cancer.
2011;128:1890–1898.
7. Rosengren A, Himmelmann A, Wilhelmsen L, et al. Hypertension
and long-term cancer incidence and mortality among Swedish men.
J Hypertens. 1998;16:933–940.
8. Grove JS, Nomura A, Severson RK, et al. The association of blood
pressure with cancer incidence in a prospective study. Am JEpidemiol. 1991;134:942–947.
9. Dyer AR, Stamler J, Berkson DM, et al. High blood-pressure: a risk
factor for cancer mortality? Lancet. 1975;1:1051–1056.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
10. Schmieder RE, Delles C, Messerli FH. Diuretic therapy and the risk
for renal cell carcinoma. J Nephrol. 2000;13:343–346.
11. Stumpe KO. Hypertension and the risk of cancer: is there new
evidence? J Hypertens. 2002;20:565–567.
12. Chow WH, McLaughlin JK, Mandel JS, et al. Risk of renal cell
cancer in relation to diuretics, antihypertensive drugs, and hyperten-
sion. Cancer Epidemiol Biomarkers Prev. 1995;4:327–331.
Medicine  Volume 94, Number 9, March 2015increase the risk of renal cell carcinoma? Am J Cardiol.
1999;83:1090–1093.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.14. Dal Moro F, Rossi A, Zattoni F. Does age really matter in the
choice of treatment for bladder cancer? Br J Cancer.
2013;108:2415–2416.
15. Wannamethee G, Shaper AG. Blood pressure and cancer in middle-
aged British men. Int J Epidemiol. 1996;25:22–31.
16. Zweifach BW. The microcirculation in experimental hypertension.
Hypertension and Bladder CancerState-of-the-art review. Hypertension. 1983;5:I10–I16.
13. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy17. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and
hypertension. Hypertension. 2011;57:132–140.
www.md-journal.com | 5
